T1	Participants 227 304	depression-related symptoms and markers of inflammation among cancer patients
T2	Participants 37 92	inflammatory markers by alleviating depressive symptoms
T3	Participants 406 422	cancer patients.
T4	Participants 581 676	newly diagnosed breast cancer patients (n = 45) with clinically significant depressive symptoms
T5	Participants 2053 2068	cancer patients
